1 October 2024
EMA/424396/2024
EMEA/H/C/003839

Public statement

Viekirax (ombitasvir / paritaprevir / ritonavir)

Withdrawal of the marketing authorisation in the European Union

On 25 September 2024, the European Commission withdrew the marketing authorisation for Viekirax (ombitasvir / paritaprevir / ritonavir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AbbVie Deutschland GmbH & Co. KG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Viekirax was granted marketing authorisation in the EU on 15 January 2015 for treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2019.

The European Public Assessment Report (EPAR) for Viekirax will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union